Related references
Note: Only part of the references are listed.Actions and mode of actions of FGF19 subfamily members
Seiji Fukumoto
ENDOCRINE JOURNAL (2008)
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis
Javier A. Menendez et al.
NATURE REVIEWS CANCER (2007)
Novel antiangiogenic pathway of thrombospondin-1 mediated by suppression of the cell cycle
Mai Yamauchi et al.
CANCER SCIENCE (2007)
Prolonged hypoxia concomitant with serum deprivation induces massive human mesenchymal stem cell death
Esther Potier et al.
TISSUE ENGINEERING (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Hypoxia-inducible factors, stem cells, and cancer
Brian Keith et al.
CELL (2007)
Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis
Lucie Kopfstein et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A perivascular niche for brain tumor stem cells
Christopher Calabrese et al.
CANCER CELL (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Hypoxia signalling in cancer and approaches to enforce tumour regression
Jacques Pouyssegur et al.
NATURE (2006)
Akt signaling and cancer: Surviving but not moving on
A Toker et al.
CANCER RESEARCH (2006)
A tumorigenic subpopulation with stem cell properties in melanomas
D Fang et al.
CANCER RESEARCH (2005)
A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1α through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma
B Das et al.
CANCER RESEARCH (2005)
FGF-21 as a novel metabolic regulator
A Kharitonenkov et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
MTOR-targeted therapy of cancer with rapamycin derivatives
S Vignot et al.
ANNALS OF ONCOLOGY (2005)
Vascular remodeling and clinical resistance to antiangiogenic cancer therapy
JG Bender et al.
DRUG RESISTANCE UPDATES (2004)
Tyrosine phosphorylation sites on FRS2α responsible for Shp2 recruitment are critical for induction of lens and retina
N Gotoh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Evolution of the Fgf and Fgfr gene families
N Itoh et al.
TRENDS IN GENETICS (2004)
Kigamicin D, a novel anticancer agent based on a new anti-austerity strategy targeting cancer cells' tolerance to nutrient starvation
J Lu et al.
CANCER SCIENCE (2004)
Why do cancers have high aerobic glycolysis?
RA Gatenby et al.
NATURE REVIEWS CANCER (2004)
Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes
K Kawada et al.
CANCER RESEARCH (2004)
Hypoxia - A key regulatory factor in tumour growth
AL Harris
NATURE REVIEWS CANCER (2002)
Involvement of chemokine receptors in breast cancer metastasis
A Müller et al.
NATURE (2001)
Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis
M Skobe et al.
NATURE MEDICINE (2001)
Structure and function of VEGF/VEGF-receptor system involved in angiogenesis
M Shibuya
CELL STRUCTURE AND FUNCTION (2001)
Possible mechanisms of acquired resistance to anti-angiogenic drugs: Implications for the use of combination therapy approaches
RS Kerbel et al.
CANCER AND METASTASIS REVIEWS (2001)
Plat-E: an efficient and stable system for transient packaging of retroviruses
S Morita et al.
GENE THERAPY (2000)
Share Paper
